Clinical trials: Cancer, Bladder
Bladder Cancer
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
Clinically node positive (cN+) bladder cancer carries a poor prognosis, especially in patients who are unable to receive or fail to respond to neoadjuvant chemotherapy.
- Trial name
- CIRTiN-BC (NCT04779489)
- Testing
- personalized ultrafractionated stereotactic ablative radiotherapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Transitional Cell Carcinoma
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
This phase II trial studies how well paclitaxel and pembrolizumab works in treating patients with urothelial cancer that has not responded to previous treatment and has spread to other places in the body.
- Trial name
- NCT02581982
- Testing
- Laboratory Biomarker Analysis, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences
Various Advanced Cancer
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
The purpose the study is to measure the effect of nivolumab (BMS-936558) in reducing tumor size in subjects with metastatic or unresectable bladder cancer.
- Trial name
- NCT02387996
- Testing
- Nivolumab
- Where
- 67 sites in United States, Australia and 9 more
- Volunteers
- 270 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer, Melanoma
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
The purpose of this study is to investigate the characteristics of tumors in patients treated with nivolumab and to identify features that help to predict a good or bad response to this drug.
- Trial name
- NCT02553642
- Testing
- Nivolumab, Nivolumab plus Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
This was the first study where BAY1163877 was given to humans. Impact of the study was to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor.
- Trial name
- NCT01976741
- Testing
- Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID
- Where
- 29 sites in United States, France and 5 more
- Volunteers
- 168 people
- Sponsor
- Bayer
Bladder Cancer
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
This is a Phase II, nonrandomized multicenter study designed to evaluate time to progression and response proportion of patients with advanced or metastatic transitional cell carcinoma of bladder receiving 6 cycles of…
- Trial name
- NCT00461851
- Testing
- Gemcitabine, Carboplatin, Sorafenib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
Urothelial Carcinoma, Bladder Cancer
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
This is a pre-surgical study involving subjects with muscle invasive bladder cancer, or urothelial cancer, who are candidates for neoadjuvant therapy.
- Trial name
- NCT02365766
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- 9 sites in United States
- Volunteers
- 83 people
- Sponsor
- Jason R. Brown
Bladder Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00981656
- Testing
- cisplatin, 5-fluorouracil, Mitomycin
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Radiation Therapy Oncology Group
Urothelial Carcinoma
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
FORT-2 is designed to evaluate safety, efficacy, RP2D and PK of rogaratinib in combination with atezolizumab in patients with untreated FGFR-positive urothelial carcinoma.
- Trial name
- FORT-2 (NCT03473756)
- Testing
- Rogaratinib (BAY1163877), Atezolizumab
- Where
- 30 sites in United States, Austria and 6 more
- Volunteers
- 37 people
- Sponsor
- Bayer
Bladder Cancer
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00526656
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Carcinoma, Transitional Cell
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
This phase II trial evaluated the impact of Oxaliplatin and Gemcitabine in patients with recurrent or advanced transitional cell carcinoma of the bladder.
- Trial name
- NCT04039867
- Testing
- Oxaliplatin with Gemcitabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Irvine
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
This phase II trial studies how well cisplatin and gemcitabine hydrochloride with or without berzosertib works in treating patients with urothelial cancer that has spread to other places in the body (metastatic).
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7
- Trial name
- NCT02567409
- Testing
- Berzosertib, Cisplatin, Gemcitabine Hydrochloride
- Where
- 39 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Anemia, Carcinoma, Non-Small-Cell Lung
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
The purpose of this study was to determine an effective and safe dose of sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia (CIA) in participants with metastatic non-small cell lung cancer (NSCLC) who are…
- Conditions
- Anemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small-Cell Lung, Bladder Cancer
- Trial name
- NCT01284348
- Testing
- Sotatercept 15 mg, Sotatercept 30 mg
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer.
- Conditions
- Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT05581589
- Testing
- Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Washington
Bladder Cancer
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
This study will enrol patients with maximally resected (via transurethral resection (TURBT) non-metastatic muscle invasive bladder cancer, who either wish to attempt bladder preservation therapy or are ineligible for cystectomy.
- Trial name
- PCR-MIB (NCT02662062)
- Testing
- Pembrolizumab, Cisplatin, Radiotherapy
- Where
- 7 sites in Australia
- Volunteers
- 28 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo
This phase II trial studies how well nivolumab works with radiation therapy in treating patients with urothelial bladder cancer that has spread from its original site of growth to nearby tissues or lymph nodes and are ineligible…
- Conditions
- Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
- Trial name
- NCT03421652
- Testing
- Nivolumab, Radiation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Bladder Cancer
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment in participants with locally advanced or metastatic urothelial bladder cancer. Participants will be enrolled into 1 of 2 cohorts.
- Trial name
- NCT02108652
- Testing
- Atezolizumab
- Where
- 77 sites in United States, Canada and 6 more
- Volunteers
- 310 people
- Sponsor
- Hoffmann-La Roche
Bladder Cancer
Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
Study participants will have been diagnosed with bladder cancer that has invaded the muscle wall of the bladder. Surgery is used to remove cancer when it is in the muscle of the bladder.
- Trial name
- NCT00585689
- Testing
- ABI-007, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan Rogel Cancer Center
Neoplasms
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
The primary objective of this trial is to evaluate the efficacy and safety of BI 6727 in patients with locally advanced, metastatic or recurrent urothelial cancer after failure of first line or adjuvant/neoadjuvant chemotherapy.
- Trial name
- NCT01023958
- Testing
- BI 6727, IV infusion
- Where
- 21 sites in United States, Taiwan
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim
Urothelial Carcinoma, Bladder Cancer
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
A Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with MIBC and in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a…
- Trial name
- NCT03869190
- Testing
- Atezolizumab, Enfortumab Vedotin, Niraparib
- Where
- 33 sites in United States, France and 5 more
- Volunteers
- 272 people
- Sponsor
- Hoffmann-La Roche